MedDataX Logo

Ancillary Study to Protocol 20060104

NCT ID: NCT00439894

Last Updated: 2008-03-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-12-31

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ancillary study to the Etanercept protocol 20060104. Subjects have been asked to provide additional blood samples for further assessment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Etanercept SFP in RA Patients

NCT00413452

Rheumatoid Arthritis
COMPLETED PHASE3

An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis

NCT00346294

Rheumatoid Arthritis
COMPLETED PHASE4

Treatment for Subjects With Active Rheumatoid Arthritis (RA)

NCT00110903

Rheumatoid Arthritis
COMPLETED PHASE3

Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry

NCT01646385

Rheumatoid Arthritis
COMPLETED

A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

NCT00888745

Rheumatoid Arthritis
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

blood draw

One time blood draw

Blood draw

Intervention Type PROCEDURE

blood draw at baseline, week 12 and week 24

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood draw

blood draw at baseline, week 12 and week 24

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed Consent Meet all inclusion critieria outlined in Amgen Protocol 20060104
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Amgen Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MD

Role: STUDY_DIRECTOR

Amgen

Related Links

Access external resources that provide additional context or updates about the study.

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20060364

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis
NCT00713544 COMPLETED PHASE2
Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis
NCT00443950 COMPLETED PHASE3
16.0040 Ankylosing Spondylitis Study
NCT00356356 COMPLETED PHASE3
Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study
NCT00522184 COMPLETED PHASE3
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
NCT00913458 COMPLETED PHASE4
Study Evaluating the Efficacy and Safety of Etanercept
NCT00546533 COMPLETED PHASE4
Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy
NCT00848354 COMPLETED PHASE4
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012
NCT00356590 COMPLETED PHASE3
Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission
NCT02373813 COMPLETED PHASE3
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
NCT00357903 COMPLETED PHASE3
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
NCT01578850 COMPLETED PHASE4
Study Evaluating the Safety of Enbrel (Etanercept)
NCT00683384 COMPLETED
Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept
NCT00459706 COMPLETED PHASE3
Enbrel Liquid Immunogenicity Protocol
NCT00249041 COMPLETED PHASE3
Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate
NCT01783015 TERMINATED PHASE4
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
NCT01411215 TERMINATED
The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept
NCT00034060 COMPLETED PHASE2
Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
NCT02378506 COMPLETED PHASE3
Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects
NCT00252668 COMPLETED PHASE4
Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
NCT01313208 COMPLETED PHASE4
Study Evaluating Enbrel in Patients With Rheumatoid Arthritis
NCT00245934 COMPLETED
This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.
NCT04267614 COMPLETED
Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients
NCT04428424 COMPLETED
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
NCT00293722 COMPLETED
A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid Arthritis
NCT00783536 WITHDRAWN PHASE4